Molecular Profiling & Clinical Trials for Pancreatic SC-NEC
At a Glance
For pancreatic small cell neuroendocrine carcinoma, molecular profiling can identify tumor mutations and immune markers that may guide targeted treatment or immunotherapy. Clinical trials should be discussed early, without delaying recommended standard chemotherapy.
Because Pancreatic Small Cell Neuroendocrine Carcinoma (SC-NEC) is so rare and aggressive, standard treatments are limited. This is why experts and international guidelines recommend looking beyond standard chemotherapy early in your journey [1][2]. Molecular profiling and clinical trials are not just “last resort” options; they are vital tools for finding personalized treatment paths.
Molecular Profiling: Mapping the Tumor
Molecular profiling, also known as Next Generation Sequencing (NGS), is a laboratory test that looks at the DNA and RNA of your cancer cells to identify specific “glitches” or mutations that drive its growth [1]. This is also known as somatic testing (testing the tumor), which is different from germline testing (testing your blood for inherited risks).
In pancreatic SC-NEC, several key biomarkers may be identified:
- TP53 and RB1 Mutations: These are the most common genetic changes in this cancer [3]. While we do not yet have drugs that “fix” these specific mutations, knowing they are present helps support the diagnosis of SC-NEC and distinguishes it from other pancreatic tumors, though they are not strictly required [4][5].
- KRAS Mutations: Found in some pancreatic NEC cases, these are common markers that researchers are currently targeting with new, experimental drugs in clinical trials [4].
- Actionable Mutations: In rare cases, profiling may find a mutation like BRAF V600E, RET fusions, or BRCA2 mutations [6][7]. If these are found, you may be eligible for “targeted therapies” originally designed for other cancers like melanoma or breast cancer, though accessing them often requires a clinical trial or off-label use [8][9].
The Role of Immunotherapy
Immunotherapy uses your body’s own immune system to fight cancer. While it is not yet a “blanket” treatment for everyone with SC-NEC, it can be an option for a small subset of patients [10].
Your doctors will look for two specific indicators on your molecular report:
- MSI-High (Microsatellite Instability): This means the cancer cells have a hard time repairing their DNA, making them look very “strange” to the immune system. While MSI-High is an established target in many cancers, it is relatively uncommon in pancreatic SC-NEC [11].
- TMB-High (Tumor Mutational Burden): This measures the total number of mutations in the tumor. A “high” score (often defined by a regulatory threshold of 10 or more mutations per megabase) suggests the tumor might respond to immunotherapy, though its predictive value in SC-NEC needs more study [1][10].
If your tumor has either of these markers, drugs like pembrolizumab or a combination of nivolumab and ipilimumab may be considered, often through a clinical trial or “off-label” use [12][13].
Why Clinical Trials are Essential
A clinical trial is a controlled research study that tests new treatments. For rare cancers like yours, clinical trials are an important way to access the most advanced science.
- Earlier is Better: You do not have to wait for your first chemotherapy to fail before considering a trial. Some trials are designed for “newly diagnosed” patients or as “maintenance” therapy after your initial response. However, enrolling should not delay time-sensitive standard chemotherapy if your team recommends starting immediately [2].
- Rare Disease Focus: Because there are so few patients with pancreatic SC-NEC, researchers often group it with other “high-grade neuroendocrine carcinomas” in large trials [12].
- New Horizons: Current trials are investigating DLL3-targeted therapies (which target a specific protein often found on small cell cancers) and new types of targeted radiation [14][15].
How to Find a Trial
Because these tumors are rare, trials are usually located at large academic medical centers. You can search for trials yourself at ClinicalTrials.gov, but the most effective way is to ask your oncologist at a high-volume center to “screen” you for any open national or international studies [16]. Finding a match often depends on having your molecular profiling results ready to share [1].
Common questions in this guide
What does molecular profiling test for in pancreatic SC-NEC?
Which genetic changes might be found in pancreatic SC-NEC?
Could immunotherapy be an option for pancreatic SC-NEC?
When should I ask about a clinical trial for pancreatic SC-NEC?
How can I find a clinical trial that matches my tumor?
Is germline testing different from tumor molecular profiling?
One line in your results can change your plan.
For a small subset, whether MSI-High or TMB-High appears on molecular profiling can determine if immunotherapy may be considered. We check your results against the latest research to help you prepare for what’s next.
Get notified when new evidence is published on pancreatic small cell neuroendocrine carcinoma.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (16)
- 1
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.
Mosele F, Remon J, Mateo J, et al.
Annals of oncology : official journal of the European Society for Medical Oncology 2020; (31(11)):1491-1505 doi:10.1016/j.annonc.2020.07.014.
PMID: 32853681 - 2
Extrapulmonary Neuroendocrine Carcinomas: Current Management and Future Perspectives.
Stumpo S, Formelli MG, Persano I, et al.
Journal of clinical medicine 2023; (12(24)) doi:10.3390/jcm12247715.
PMID: 38137784 - 3
Molecular profiling and target actionability for precision medicine in neuroendocrine neoplasms: real-world data.
Boilève A, Faron M, Fodil-Cherif S, et al.
European journal of cancer (Oxford, England : 1990) 2023; (186()):122-132 doi:10.1016/j.ejca.2023.03.024.
PMID: 37062210 - 4
Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study.
Hijioka S, Hosoda W, Matsuo K, et al.
Clinical cancer research : an official journal of the American Association for Cancer Research 2017; (23(16)):4625-4632 doi:10.1158/1078-0432.CCR-16-3135.
PMID: 28455360 - 5
A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
Tang LH, Basturk O, Sue JJ, Klimstra DS
The American journal of surgical pathology 2016; (40(9)):1192-202 doi:10.1097/PAS.0000000000000662.
PMID: 27259015 - 6
Primary Resistance to RET Inhibition in a RET Fusion-Positive Pancreatic Neuroendocrine Carcinoma.
McKinley BJ, Coston TW, Starr JS
The oncologist 2025; (30(1)) doi:10.1093/oncolo/oyae034.
PMID: 38478398 - 7
Case Report: Deep and durable response to talazoparib in germline BRCA2-mutated rectal neuroendocrine carcinoma.
Khealani M, Park BU, Schat R, et al.
Frontiers in oncology 2025; (15()):1705579 doi:10.3389/fonc.2025.1705579.
PMID: 41487567 - 8
Future therapeutic strategies in the treatment of extrapulmonary neuroendocrine carcinoma: a review.
Robinson MD, Livesey D, Hubner RA, et al.
Therapeutic advances in medical oncology 2023; (15()):17588359231156870 doi:10.1177/17588359231156870.
PMID: 36872945 - 9
Efficacy of BRAF inhibitor and anti-EGFR antibody in colorectal neuroendocrine carcinoma.
Nakano M, Shimada Y, Matsumoto Y, et al.
Clinical journal of gastroenterology 2022; (15(2)):413-418 doi:10.1007/s12328-022-01599-4.
PMID: 35133626 - 10
Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas.
Raj N, Chan JA, Wang SJ, et al.
British journal of cancer 2023; (129(2)):291-300 doi:10.1038/s41416-023-02298-8.
PMID: 37208512 - 11
Microsatellite instability in pancreatic and ampullary carcinomas: histology, molecular pathology, and clinical implications.
Luchini C, Scarpa A
Human pathology 2023; (132()):176-182 doi:10.1016/j.humpath.2022.06.009.
PMID: 35714836 - 12
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors.
Patel SP, Othus M, Chae YK, et al.
Clinical cancer research : an official journal of the American Association for Cancer Research 2020; (26(10)):2290-2296 doi:10.1158/1078-0432.CCR-19-3356.
PMID: 31969335 - 13
A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohort.
Patel SP, Mayerson E, Chae YK, et al.
Cancer 2021; (127(17)):3194-3201 doi:10.1002/cncr.33591.
PMID: 33882143 - 14
Delta-like ligand 3 expression and functional imaging in gastroenteropancreatic neuroendocrine neoplasms.
Thummalapalli R, Tendler S, Chou JF, et al.
medRxiv : the preprint server for health sciences 2025; doi:10.1101/2025.06.24.25330227.
PMID: 40666328 - 15
PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3).
Sorbye H, Kong G, Grozinsky-Glasberg S
Endocrine-related cancer 2020; (27(3)):R67-R77.
PMID: 31846429 - 16
Neoplasms of the Neuroendocrine Pancreas: An Update in the Classification, Definition, and Molecular Genetic Advances.
Guilmette JM, Nosé V
Advances in anatomic pathology 2019; (26(1)):13-30 doi:10.1097/PAP.0000000000000201.
PMID: 29912000
This page explains molecular profiling and clinical-trial options for pancreatic SC-NEC for informational purposes only and is not medical advice. Your oncology team should interpret your report and decide whether testing, immunotherapy, or a clinical trial is appropriate for you.